Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF prophylaxis for HBV reactivation in HBsAg-positive DLBCL/CLL patients receiving rituximab-based chemotherapy
2019-000159-14Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir alafenamide in hepatitis B (HBV) and Hepatitis B reactivation (HBVr), sponsored by GIMEMA. Primary endpoint: Incidence of HBV reactivation within 6 months. Started Dec 2020; status: terminated.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)Hepatitis B reactivation (HBVr)
Beyond the preview
Go deeper on 2019-000159-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000159-14.